Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Parkinson's Disease: early-phase trial registry
42 of 161 indexed Parkinson's Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #67 of 28,707 conditions by registered trial count.
161 US clinical trials · 42 currently recruiting · #67 of 28,707 conditions by registered trial count
Parkinson's Disease: 161 US clinical trials tracked, 42 recruiting.
Parkinson's Disease is the subject of 161 registered US clinical trials on ClinicalTrials.gov, 42 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 55 in Phase 1-2 (earlier-stage). The most active sponsor is VA Office of Research and Development, running 16 of these trials.
Enrollment posture brief
Registry condition parkinsons-disease
OPEN 42 | RECR 26% | LATE 21 | EARLY 55 | RANK #67 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Barrett's Esophagus (26% recruiting · 23 trials)
Parkinson's Disease lists 42 open slots (26% of 161 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Parkinson's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Parkinson's Disease is recruiting below its size-band peers.
42 of 161 indexed trials (26.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Parkinson's Disease trials is spread across many organizations.
VA Office of Research and Development accounts for 16 of 161 trials (9.9%). 99 distinct sponsors appear on at least one study for this condition label.
-
Most Parkinson's Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 51 among the 159 trials that report a genuine target (sentinel values excluded). 100 of those (62.9%) plan for fewer than 100 participants.
-
Parkinson's Disease research is mostly interventional.
114 interventional and 47 observational studies make up this index (70.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
161 total, page 2 of 4
Noninterventional Study Evaluating Parkinson's Disease Diary Use
BlueRock Therapeutics
NCT05363046
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
AskBio
NCT05699460
The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry
Scripps Translational Science Institute
NCT00766948
Clinical Laboratory Evaluation of Chronic Autonomic Failure
National Institute of Neurological Disorders and Stroke (NINDS)
NCT03648905
Partnered Dance Aerobic Exercise as a Neuroprotective, Motor and Cognitive Intervention in Parkinson's Disease
VA Office of Research and Development
NCT04122690
Cont. of a Study to Evaluate Implanting Peripheral Nerve Grafts Into Subjects With Parkinson's Disease (PD) During DBS
Craig van Horne, MD, PhD
NCT02369003
Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease
Massachusetts General Hospital
NCT02909192
Genotypic Influences on Network Progression in Parkinson's Disease
Northwell Health
NCT04228172
Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
MeiraGTx
NCT05894343
GDNF Gene Therapy for Parkinson's Disease
Brain Neurotherapy Bio
NCT04167540
Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)
Craig van Horne, MD, PhD
NCT05377281
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
InSightec
NCT02246374
Web-based Genetic Research on Parkinson's Disease
23andMe
NCT01351467
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)
Columbia University
NCT00104585
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Teva Branded Pharmaceutical Products R&D
NCT00936676
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
Impax Laboratories
NCT01096186
Diagnosis and Natural History Study of Patients With Neurological Conditions
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001549
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
UCB Pharma
NCT00522379
PET Scanning in Parkinson s Disease
National Institute of Mental Health (NIMH)
NCT00024622
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
GlaxoSmithKline
NCT00632736
Haptoglobin and Iron in Parkinson's Disease
Bastyr University
NCT02422992
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
Teva Neuroscience
NCT01049984
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
Kyowa Kirin
NCT00456794
Study of Urate Elevation in Parkinson's Disease, Phase 3
Michael Alan Schwarzschild
NCT02642393
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
Teva Branded Pharmaceutical Products R&D
NCT00203164
Pioglitazone in Early Parkinson's Disease
University of Rochester
NCT01280123
Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)
GE Healthcare
NCT01952678
National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial
University of Rochester
NCT00063193
Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease
Juvantia Pharma
NCT00559871
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
Teva Branded Pharmaceutical Products R&D
NCT01723228
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
Kyowa Kirin
NCT00199433
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Pharma Two B
NCT01968460
Deep Brain Stimulation for Parkinson's Disease Trial
University of Minnesota
NCT00053625
Mobile Decision Support System for Nurse Management of Neuromodulation Therapy
University of Utah
NCT02474459
Neuroimaging Studies of Depression in Parkinson's Disease
Lee Blonder
NCT00518258
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
Impax Laboratories
NCT01130493
Cognitive Rehabilitation for PD
VA Office of Research and Development
NCT03335150
An RCT of a Telemedicine Intervention for Hypokinetic Dysarthria in PD
VA Office of Research and Development
NCT04617496
Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes
Emory University
NCT02749214
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Beth Israel Deaconess Medical Center
NCT02118805
Exercise, Brain Imaging, Cognition, and Gait in Parkinsonism
Oregon Health and Science University
NCT02231073
Valerian to Improve Sleep in Patients With Parkinson's Disease
National Center for Complementary and Integrative Health (NCCIH)
NCT00070928
Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease
University of Michigan
NCT00737217
Validation of Dyskinesia Rating Scales
Rush University Medical Center
NCT01071395
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
VA Office of Research and Development
NCT01106976
Early Parkinson's Disease Monotherapy With CVN424
Cerevance Beta
NCT06006247
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
Teva Branded Pharmaceutical Products R&D
NCT01879748
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
Ionis Pharmaceuticals
NCT03976349
Safety and Efficacy of DA-9805 for Parkinson's Disease
Dong-A ST Co.
NCT03189563
Diagnosis of PD and PD Progression Using DWI
University of Alabama at Birmingham
NCT02837172
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 31 |
| Phase 3 | 11 |
| Phase 4 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Parkinson's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Parkinson's Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Parkinson's Disease page
161 registered trials, 42 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 42 Parkinson's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- VA Office of Research and Development sponsors the most Parkinson's Disease trials on record, review their full trial history before evaluating a specific study. See VA Office of Research and Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Parkinson's Disease condition card totals 161 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.